Q3 Revenue Up 8%, Guidance Held, But CEO Warns GLP-1 Slowdown Will Cap 2027 Growth
STVN sits 53% above its 52-week low of $12.89 on elevated volume (2.0× avg).
Summary
Third-quarter revenue rose 8% to €326.1 million, entirely organic, with adjusted EBITDA margin up 150 basis points to 27.2% and adjusted diluted EPS up 14% to €0.16. The Biopharmaceutical and Diagnostic Solutions segment grew 11% organically, offsetting a 12% decline in Engineering. Full-year 2026 guidance is unchanged: revenue of €1.260-1.280 billion, adjusted EBITDA of €335.0-345.2 million, and adjusted diluted EPS of €0.60-0.62. The problem is the outlook. CEO Franco Stevanato said the company now expects lower GLP-1 volumes than previously anticipated, which will temporarily moderate growth in 2027, with only low single-digit growth expected based on what is known today. GLP-1 therapies were roughly 17-18% of third-quarter revenue, so a softer GLP-1 trajectory hits a meaningful slice of the base even as non-GLP-1 biologics grew over 30%. The quarter itself is solid and in line with expectations; the 2027 commentary is what changes the story. Management is on the call at 8:30 a.m. ET today.
At the time of this announcement, STVN was trading at $19.74 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $12.89 to $27.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.